A study published by ASCO Publications on October 20, 2026 examines how circulating eosinophils relate to systemic immune activation and recurrence in hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. According to ASCO Publications, the research associates these immune cells with signs of broader immune system activity and with a reduced likelihood of the cancer returning.
The work focuses on a specific subtype of breast cancer defined by its hormone receptor status and the absence of HER2 amplification. In this group, the authors looked at eosinophils — white blood cells typically associated with allergic responses and defense against parasites — as they appear in the bloodstream, and connected their presence to immune activation throughout the body.
The headline finding, as reported by ASCO Publications, is a link between circulating eosinophils, systemic immune activation, and lower recurrence. The summary does not disclose patient numbers, follow-up periods, or effect sizes, and those details would be needed to judge how strong the association is.
The report adds to a growing line of inquiry into whether immune signals visible in routine blood work can inform prognosis in breast cancer. Because the available summary offers only the headline conclusion, questions about whether the relationship holds across treatment groups or disease stages remain open.
Watch for the full study data, including cohort size and statistical measures, which would clarify whether eosinophil counts could eventually serve as a prognostic marker in this patient population.
